Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.79% | 3.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.33% | 78.11% | |||
| Operating Income | -29.33% | -78.11% | |||
| Income Before Tax | -30.99% | -82.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.99% | -82.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.99% | -82.23% | |||
| EBIT | -29.33% | -78.11% | |||
| EBITDA | -29.39% | -78.35% | |||
| EPS Basic | -20.44% | -48.99% | |||
| Normalized Basic EPS | -20.46% | -48.94% | |||
| EPS Diluted | -20.44% | -48.99% | |||
| Normalized Diluted EPS | -20.46% | -48.94% | |||
| Average Basic Shares Outstanding | 8.76% | 22.33% | |||
| Average Diluted Shares Outstanding | 8.76% | 22.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||